Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/63704
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3645]
Metadata
Show full item record
PREVALENCE AND IMPACT OF SARCOPENIA IN INDIVIDUALS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (THE SARC-HF STUDY): A PROSPECTIVE OBSERVATIONAL STUDY PROTOCOL
Author
Nascimento, Pablo Marino Corrêa
Rodrigues Junior, Luiz Fernando
Mediano, Mauro Felippe Felix
Silva, Valéria Gonçalves da
Tura, Bernardo Rangel
Nogueira, Fabio César Sousa
Domont, Gilberto
Carvalho, Adriana Bastos
Carvalho, Antônio Carlos Campos de
Kasai-Brunswick, Taís Hanae
Mesquita, Claudio Tinoco
Villacorta Junior, Humberto
Rey, Helena Cramer Veiga
Rodrigues Junior, Luiz Fernando
Mediano, Mauro Felippe Felix
Silva, Valéria Gonçalves da
Tura, Bernardo Rangel
Nogueira, Fabio César Sousa
Domont, Gilberto
Carvalho, Adriana Bastos
Carvalho, Antônio Carlos Campos de
Kasai-Brunswick, Taís Hanae
Mesquita, Claudio Tinoco
Villacorta Junior, Humberto
Rey, Helena Cramer Veiga
Affilliation
National Institute of Cardiology. Rio de Janeiro, RJ, Brazil / Fluminense Federal University. Niterói, RJ, Brazil.
National Institute of Cardiology. Rio de Janeiro, RJ, Brazil / Federal University of the State of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
National Institute of Cardiology. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Chagas Disease Clinical Research Laboratory. Rio de Janeiro, RJ, Brazil.
National Institute of Cardiology. Rio de Janeiro, RJ, Brazil.
National Institute of Cardiology. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
National Institute of Cardiology. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
National Institute of Cardiology. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
National Institute of Cardiology. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
Fluminense Federal University. Niterói, RJ, Brazil.
Fluminense Federal University. Niterói, RJ, Brazil.
National Institute of Cardiology. Rio de Janeiro, RJ, Brazil.
National Institute of Cardiology. Rio de Janeiro, RJ, Brazil / Federal University of the State of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
National Institute of Cardiology. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Evandro Chagas National Institute of Infectious Diseases. Chagas Disease Clinical Research Laboratory. Rio de Janeiro, RJ, Brazil.
National Institute of Cardiology. Rio de Janeiro, RJ, Brazil.
National Institute of Cardiology. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
National Institute of Cardiology. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
National Institute of Cardiology. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
National Institute of Cardiology. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
Fluminense Federal University. Niterói, RJ, Brazil.
Fluminense Federal University. Niterói, RJ, Brazil.
National Institute of Cardiology. Rio de Janeiro, RJ, Brazil.
Abstract
Sarcopenia, a clinical syndrome primarily associated with reduced muscle mass in the elderly, has a negative impact on quality of life and survival. It can occur secondarily to other diseases such as heart failure (HF), a complex clinical syndrome with high morbidity and mortality. The simultaneous occurrence of these two conditions can worsen the prognosis of their carriers, especially in the most severe cases of HF, as in patients with reduced left ventricular ejection fraction (LVEF). However, due to the heterogeneous diagnostic criteria for sarcopenia, estimates of its prevalence present a wide variation, leading to new criteria having been recently proposed for its diagnosis, emphasizing muscle strength and function rather than skeletal muscle mass. The primary objective of this study is to evaluate the prevalence of sarcopenia and/or dynapenia in individuals with HF with reduced LVEF according to the most recent criteria, and compare the gene and protein expression of those patients with and without sarcopenia. The secondary objectives are to evaluate the association of sarcopenia and/or dynapenia with the risk of clinical events and death, quality of life, cardiorespiratory capacity, ventilatory efficiency, and respiratory muscle strength. The participants will answer questionnaires to evaluate sarcopenia and quality of life, and will undergo the following tests: handgrip strength, gait speed, dual-energy X-ray absorptiometry, respiratory muscle strength, cardiopulmonary exercise, as well as genomic and proteomic analysis, and dosage of N-terminal pro-B-type natriuretic peptide and growth differentiation factor-15. An association between sarcopenia and/or dynapenia with unfavorable clinical evolution is expected to be found, in addition to reduced quality of life, cardiorespiratory capacity, ventilatory efficiency, and respiratory muscle strength.
Share